



## Original Article

# Six-year multicenter study on short-term peripheral venous catheters-related bloodstream infection rates in 246 intensive units of 83 hospitals in 52 cities of 14 countries of Middle East: Bahrain, Egypt, Iran, Jordan, Kingdom of Saudi Arabia, Kuwait, Lebanon, Morocco, Pakistan, Palestine, Sudan, Tunisia, Turkey, and United Arab Emirates—International Nosocomial Infection Control Consortium (INICC) findings<sup>☆</sup>

Víctor D. Rosenthal<sup>a,\*</sup>, Souad Belkebir<sup>b</sup>, Farid Zand<sup>c</sup>, Majeda Afeef<sup>d</sup>, Vito L. Tanzi<sup>e</sup>, Hail M. Al-Abdely<sup>f</sup>, Amani El-Kholy<sup>g</sup>, Safa A. Aziz AlKhawaja<sup>h</sup>, Ali P. Demiroz<sup>i</sup>, Amani F. Sayed<sup>j</sup>, Naheed Elahi<sup>k</sup>, May O. Gamar-Elanbya<sup>l</sup>, Khalid Abidi<sup>m</sup>, Najla Ben-Jaballah<sup>n</sup>, Mona F. Salama<sup>o</sup>, Najla J. Helali<sup>p</sup>, Mona M. Abdel-Halim<sup>q</sup>, Nadia L. Demaisip<sup>r</sup>, Hala Ahmed<sup>s</sup>, Hanan H. Diab<sup>t</sup>, Apsia M. Molano<sup>u</sup>, Fahad A. Sawan<sup>v</sup>, Ashraf Kelany<sup>w</sup>, Rami Altowerqi<sup>x</sup>, Hala Rushdi<sup>y</sup>, Modhi A. Alkamaly<sup>z</sup>, Eatedal Bohlega<sup>A</sup>, Hajer A. Aldossary<sup>B</sup>, Kareem M. Abdelhady<sup>C</sup>, Amer Ikram<sup>D</sup>, Marjory Madco<sup>E</sup>, Yvonne Caminade<sup>F</sup>, Muneefah Alazmi<sup>G</sup>, Tahsine Mahfouz<sup>H</sup>, Reham H. Abdelaziz-Yousef<sup>I</sup>, Ahmed Ibrahim<sup>J</sup>, Basma Elawady<sup>K</sup>, Tasmiya Asad<sup>L</sup>, Leide Shyrine<sup>M</sup>, Hakan Leblebicioglu<sup>N</sup>

<sup>a</sup> International Nosocomial Infection Control Consortium, Buenos Aires, Argentina

<sup>b</sup> Assistant professor, An Najah National University, An Najah University Hospital, Nablus, Palestine

<sup>c</sup> Anesthesiology and Critical Care Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

<sup>☆</sup> Remaining co-authors of this study: **Bahrain:** Saeed, N.K.; Abdul-Aziz, S.; ALSayegh, S.; Humood, M.Z.; Mohamed-Ali, K.; Swar, S.; Magray, T.A.S. **Egypt:** Bayani, V.; Ahmed, S.A.; Alansary, A.M.; Hassan, A.R.; Abdulloriz-Ghazi, I.; El-Fattah, M.A.; Hala, A.; Ahmed-Fouad, H.; Mounir-Agha, H.; Hamza, H.S.; Salah, Z.; Abdel-Aziz, D.M.; Ibrahim, S.B.; Helal, A.M.; Abdel-Massih, A.F.; Reham-Mahmoud, A.; Elawady, B.; El-sheerif, R.H.; Fattah-Radwan, Y.A.; Abdel-Mawla, T.S.; Kamal-Elden, N.M.; Abdelhamid, Y.; Fouda, R.; Mohammed-Hassan, D.; Mansour, M. **Iran:** Masjedi, M.; Maghsudi, B.; Sabetian, G.; Sanaei, A.; Yousefipour, A.; Nikandish, R.; Sanaei, A.; Shafiee E.; Paydar, S.; Khalili, H.A.; Moradi, A.; Sadeghi, P.; Bolandparvaz, S. **Jordan:** Mubarak, S.; Makhoulouf, M.; Awwad, M.; Ayyad, O.; Shaweesh, A.A.; Khader, M.M.; Alghazawi, A.; Hussien, N.; Alruzzieh, M. **Kingdom of Saudi Arabia:** Mohamed, Y.K.; ALazhary, M.; Abdul Aziz, O.A.; Alazmi, M.; Mendoza, J.; De Vera, P.A.; Rillorta, A.S.; Mildred-de-Guzman; Girvan, M.; Torres, M.; Alzahrani, N.; Alfaraj, S.; Gopal, U.; Manuel, M.G.; Alshehri, R.; Lessing, L.; Alzoman, H.; Abdrahim, J.; Adballah, H.; Thankachan, J.; Gomaa, H.; Asad, T.; AL-Alawi, M.; AL-Abdullah, N.A.; Demaisip, N.L.; Laungayan-Cortez, E.; Cabato, A.F.; Gonzales, J.M.; Al Raey, M.A.; Al-Darani, S.A.; Aziz, M.R.; Al-Manea, B.; Samy, E.; AlDalaton, M.; Alaliany, M.J.; Alabdely, H.M.; Helali, N.J.; Sindayen, G.; Malificio, A.A.; Al-Dossari, H.B.; Kelany, A.; Algethami, A.G.; Mohamed, D.; Yanne, L.; Tan, A.; Babu, S.; Abduljabbar, S.M.; Al-Zaydani, M.A.; Al Jarie, A.; Al-Qathani, A.S.M.; Al-alkami, H.Y.; AlDalaton, M.; Alih, S.J.B.; Alaliany, M.J.; Gasmin-Aromin, R.; Balon-Ubalde, E.; Diab, H.H.; Kader, N.A.; Hassan-Assiry, I.Y.; Kelany, A.; Albeladi, E.; Aboushoushah, S.; Qushmaq, N.; Fernandez, J.; Hussain, W.M.; Rajavel, R.D.; Bukhari, S.Z.; Rushdi, H.; Turkistani, A.A.; Mushtaq, J.J.; Bohlega, E.; Simon, S.; Damlig, E.; Elsherbini, S.G.; Abraham, S.; Kaid, E.; Al-Attas, A.; Hawsawi, G.; Hussein, B.; Esam, B.; Caminade, Y.; Santos, A.J.; Abdulwahab, M.H.; Aldossary, A.H.; Al-Suliman, S.; Al-Talib, A.A.; Albaghly, N.; HaqlreMia, M.E.; Kaid, E.; Altowerqi, R.; Ghalilah, K.M.; Alradady, M.; Al-Qatri, A.; Chaouali, M.; Shyrine, E.L.; Philipose, J.; Raees, M.; Abdulkhalik, N.S.; Madco, M.; Acostan, C.; Safwat, R.; Halwani, M.; Abdul-Aal, N.A.H.; Thomas, A.; Abdulatif, S.M.; Ali-Karrar, M.A.; Al-Gosn, N.; Al-Hindi, A.A.; Jaha, R.N.; AlQahani, S.N.; Ayugat, E.P.; Al-Hussain, M.I.; Aldossary, A.; Al-Suliman, S.; Al-Talib, A.A.; Albaghly, N.; Haqlre-Mia, M.E.; Briones, S.; Krishnan, R.; Tabassum, K.; Alharbi, L.; Madani, A.; Al-Hindi, A.A.; Al-Gethamy, M.A.; Alalmri, D.M.; Mahmoud, A. **Kuwait:** Kurian, A.; George, S.M.; Mohamed, A.M.; Ramapurath, R.J.; Varghese, S.T.; Abdo, N.M. Foda-Salama, M.; Al-Mousa, H.H.; Omar, A.A.; Toleb, M.; Khamis, S. **Lebanon:** Kanj, S.S.; Zahreddine, N.K.; Kanafani, Z.; Kardas, T.; Ahmadi, R.; Hammoud, Z.; Zeid, I.; Al-Souheil, A.; Ayash, H. **Morocco:** Madani, N.; Abouqal, R.; Zeggwagh, A. A.; Berechid, K.; Dendane, TP.; **Nepal:** Koirala, A.; Giri, R.; Sainju, S.; Acharya, S.P. **Pakistan:** Paul, N.; Parveen, A.; Raza, A.; Nizamuddin, S.; Sultan, F.; Imran, F.; Sajjad, R.; Khan, M.; Sana, F.; Tayyab, N.; Ahmed, A.; Zaman, G.; Khan, I.; Khurram, F.; Hussain, A.; Zahra, F.T.; Imtiaz, A.; Daud, N.; Sarwar, M.; Roop, Z.; Yusuf, S.; Hanif, F.; Shumaila; Zeb, J.; Ali, S.R.; Demas, S.; Ariff, S.; Riaz, A.; Hussain, A.S. **Palestine:** Kanaan, A.; Jeetawi, R. **Tunisia:** Borgi, A.; Bouziri, A. **Turkey:** Tuncer, G.E.; Bulut, C.; Hatipoglu, C.A.; Sebnem, F.E.; Kaya, A.; Ersoz, G.; Kuyucu, N.; Karacorlu, S.; Gorennek, L.; Erdem, H.; Yildizdas, D.; Horoz, O.O.; Guclu, E.; Kaya, G.; Karabay, O.; Altindis, M.; Oztoprak, N.; Sahip, Y.; Uzun, C.; Erben, N.; Usluer, G.; Ozgunes, I.; Ozcelik, M.; Ceyda, B.M.; Oral, M.; Unal, N.; Cigdem, Y.G.; Bayar, M.K.; Bermede, O.; Saygili, S.; Yesiler, I.; Memikoglu, O.; Oncul, A.; Ozdemir, D.; Geyik, M.F.; Erdogan, S.Y.; Dilek, A.; Esen, S.; Turgut, H.; Sungurtekin, H.; Ugurcan, D.; Yarar, V.; Bilir, Y.; Bayram, N.; Devrim, I.; Agin, H.; Ceylan, G.; Yasar, N.; Oruc, Y.; Ramazanoglu, A.; Turhan, O.; Cengiz, M.; Yalcin, A.N.; Dursun, O.; Gunasan, P.; Kaya, S.; Senol, G.; Gululu, A.; Arman, D.; Gelebek, Y.; Zengin, H. **United Arab Emirates:** Al-Rahma, H.; Annamma, P.; El-Houfi, A.

\* Corresponding author at: International Nosocomial Infection Control Consortium (INICC), 11 de Septiembre 4567, Floor 12, Apt 1201, Buenos Aires 1429, Argentina.

E-mail address: [victor.rosenthal@inicc.org](mailto:victor.rosenthal@inicc.org) (V.D. Rosenthal).

<sup>1</sup> [www.INICC.org](http://www.INICC.org) [victor.rosenthal@inicc.org](mailto:victor.rosenthal@inicc.org).

<https://doi.org/10.1016/j.jiph.2020.03.012>

1876-0341/© 2020 Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

- <sup>d</sup> King Hussein Cancer Center, Amman, Jordan  
<sup>e</sup> Hammoud Hospital University Medical Center, Saida, Lebanon  
<sup>f</sup> General Directorate of Infection Prevention and Control, Ministry of Health, Saudi Arabia  
<sup>g</sup> Dar Al Fouad Hospital, 6th of October City, and Cairo University Hospital, Cairo, Egypt  
<sup>h</sup> General Directorate of Infection Prevention and Control, Ministry of Health, Bahrain  
<sup>i</sup> Ankara Training and Research Hospital, Ankara, Turkey  
<sup>j</sup> Farwaniya Hospital, Kuwait City, Kuwait  
<sup>k</sup> Dubai Hospital, Dubai, United Arab Emirates  
<sup>l</sup> Royal Care International Hospital, Khartoum, Sudan  
<sup>m</sup> Ibn Sina Hospital of Morocco, Rabat, Morocco  
<sup>n</sup> Children Hospital Bechir Hamza of Tunis, Tunis, Tunisia  
<sup>o</sup> Mubarak Al Kabir, Kuwait City, Kuwait  
<sup>p</sup> King Abdulaziz Specialist Hospital, Taif, Saudi Arabia  
<sup>q</sup> Children Hospital Cairo University Abu El Reesh, Cairo, Egypt  
<sup>r</sup> Assir Central Hospital, Assir, Saudi Arabia  
<sup>s</sup> Abha Maternity And Children Hospital, Assir, Saudi Arabia  
<sup>t</sup> King Khalid Hospital, Najran, Saudi Arabia  
<sup>u</sup> King Khalid Hospital, Tabuk, Saudi Arabia  
<sup>v</sup> King Fahad Central Hospital, Jizan, Saudi Arabia  
<sup>w</sup> King Abdulaziz Hospital and Oncology Center, Makkah, Saudi Arabia  
<sup>x</sup> King Abdullah Medical Complex, Jeddah, Saudi Arabia  
<sup>y</sup> Hera General Hospital, Makkah, Saudi Arabia  
<sup>z</sup> King Khalid Hospital, Hail, Saudi Arabia  
<sup>A</sup> King Salman Hospital, Riyadh, Saudi Arabia  
<sup>B</sup> Dammam Maternity and Children Hospital, Dammam, Saudi Arabia  
<sup>C</sup> Cairo University Specialized Pediatric Hospital, Cairo, Egypt  
<sup>D</sup> Armed Forces Institute of Pathology, Rawalpindi, Pakistan  
<sup>E</sup> King Fahad Hospital, Jeddah, Saudi Arabia  
<sup>F</sup> King Feisal Hospital, Taif, Saudi Arabia  
<sup>G</sup> Prince Momhamed Bin Abdul Aziz Hospital, Riyadh, Saudi Arabia  
<sup>H</sup> Sheikh Ragheb Harb Hospital, Nabatieh, Lebanon  
<sup>I</sup> Internal Medicine Hospital, Cairo, Egypt  
<sup>J</sup> King Fahad Hospital, Al Hasa, Saudi Arabia  
<sup>K</sup> New Obgyn Kasr Alainy Hospital, Riyadh, Saudi Arabia  
<sup>L</sup> King Saud Medical City of Riyadh, Riyadh, Saudi Arabia  
<sup>M</sup> King Saud Hospital, Qassim, Saudi Arabia  
<sup>N</sup> Ondokuz Mayıs University Medical School, Samsun, Turkey

## ARTICLE INFO

### Article history:

Received 18 August 2019  
 Received in revised form 29 January 2020  
 Accepted 16 March 2020

### Keywords:

Hospital infection  
 Device-associated infections  
 Antibiotic resistance  
 Peripheral line-associated bloodstream infections  
 Mortality  
 Intensive care unit  
 Surveillance

## ABSTRACT

**Background:** Short-term peripheral venous catheters-related bloodstream infections (PVC-BSIs) rates have not been systematically studied, and data on their incidence by number of device-days is not available.

**Methods:** Prospective, surveillance study on PVC-BSI conducted from September 1st, 2013 to 31st Mays, 2019 in 246 intensive care units (ICUs), members of the International Nosocomial Infection Control Consortium (INICC), from 83 hospitals in 52 cities of 14 countries in the Middle East (Bahrain, Egypt, Iran, Jordan, Kingdom of Saudi Arabia, Kuwait, Lebanon, Morocco, Pakistan, Palestine, Sudan, Tunisia, Turkey, and United Arab Emirates). We applied U.S.

**Results:** We followed 31,083 ICU patients for 189,834 bed-days and 202,375 short term peripheral venous catheter (PVC)-days. We identified 470 PVC-BSIs, amounting to a rate of 2.32/1000 PVC-days. Mortality in patients with PVC but without PVC-BSI was 10.38%, and 29.36% in patients with PVC and PVC-BSI. The mean length of stay in patients with PVC but without PVC-BSI was 5.94 days, and 16.84 days in patients with PVC and PVC-BSI. The microorganism profile showed 55.2 % of gram-positive bacteria, with Coagulase-negative *Staphylococci* (31%) and *Staphylococcus aureus* (14%) being the predominant ones. Gram-negative bacteria accounted for 39% of cases, and included: *Escherichia coli* (7%), *Klebsiella pneumoniae* (8%), *Pseudomonas aeruginosa* (5%), *Enterobacter* spp. (3%), and others (29.9%), such as *Serratia marcescens*.

**Conclusions:** PVC-BSI rates found in our ICUs were much higher than rates published from USA, Australia, and Italy. Infection prevention programs must be implemented to reduce the incidence of PVC-BSIs.

© 2020 Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Short-term peripheral venous catheter (PVC) therapy is one of the most common invasive procedure performed in health care settings worldwide [1–3]. As stated in different point-prevalence studies, PVCs accounted to 80%, 90% and 95% of all intravascular devices placed in hospitalized patients in France, in Scotland, and Spain, respectively [3]. According to a recent systematic review,

PVCs are widely used, amount to 200 millions of PVCs being inserted in the US each year [3].

It has been reported in the mainstream literature that the overall PVC failure rate ranges from 35% to 50% [1,2,4], with such failures being responsible for causing PVC-related adverse events, such as phlebitis, occlusion/mechanical failure, infiltration, dislodgment, and bloodstream infections (BSIs) [1,2,4–9]. Moreover, the men-

tioned it was reported that the high prevalence of PVCs being inserted regularly has resulted in considerable morbidity, excess length of stay (LOS) and hospital costs, prolonged antibiotics treatments, and BSIs [10].

PVCs have been rarely associated with bloodstream infections (BSIs), as stated in the 2011 CDC guidelines for the prevention of intravascular catheter-related BSIs [3,11,12]; as a consequence, most studies have therefore been focused on central line-associated BSIs, rather than PVC-related bloodstream infections (PVC-BSIs), which to date have not been thoroughly analyzed [10].

PVC-BSIs are confirmed by the presence of positive blood cultures related by clinical data to PVCs [1]. The incidence of PVC-BSIs in ICU patients has been reported to be 0.5 per 1000 PVCs-days in ICUs from Australia, Italy and the US [12], and 0.67 PVC-BSIs per 1000 PVCs-days in pediatric and neonatal ICUs from Australia [13]. As for the incidence of PVC-BSI in other countries, there is a gap in the literature, as comprehensive data remains not available. In accordance with the 2016 Infusion Nurses Society standards of practice [14] and the 2017 International Nosocomial Infection Control Consortium (INICC) Bundle for the prevention of central and peripheral lines-related BSIs that there is no time limit recommended for PVC removal [15].

This prospective surveillance, which was conducted during 6 years, between September 1<sup>st</sup>, 2013 and May 31<sup>st</sup>, 2019, in 246 ICUs in 83 hospitals that participate in INICC [6–8,16], is the first comprehensive one conducted in 52 cities in 14 countries of the Eastern Mediterranean Region (Bahrain, Egypt, Iran, Jordan, Kingdom of Saudi Arabia, Kuwait, Lebanon, Morocco, Pakistan, Palestine, Sudan, Tunisia, Turkey, and United Arab Emirates) as a first step to analyze the incidence rate, bacterial resistance, LOS and mortality attributable to PVC-BSI.

## Methods

### Background on INICC

INICC is comprised of a group of hospitals, in 210 cities, in 54 countries in the six World Health Organization (WHO) regions: Africa, the Americas, Eastern Mediterranean, Europe, South East Asia, and Western Pacific, and has become the oldest and largest source of aggregate standardized international data on the epidemiology of healthcare-associated infections (HAIs) worldwide [6,17]. INICC's main goal is the prevention of HAIs in adult, pediatric and neonatal ICUs, step down units, inpatient wards, and of surgical site infections in surgical procedures hospital-wide through systematic outcome and process surveillance, and implementation of multidimensional infection control programs.

### Study design

This prospective, cohort surveillance study was conducted by means of an online platform called INICC Surveillance Online System (ISOS). Through ISOS, validation of each PVC-BSI was checked by infection control professionals (ICPs) and the recorded signs and symptoms of infection and the results of cultures, laboratory and radiographic studies, as well as other tests, are scrutinized to assure that the last U.S. CDC-NHSN criteria for PVC-BSIs were met, in accordance with the definition presented below [17,18].

### INICC methods

The ISOS includes the implementation of CDC/NHSN's methodology, but adds the collection of other data essential to increase ICPs' sensitivity of to detect PVC-BSIs, and avoid underreporting [17]. According to standard CDC/NHSN methods, numerators are the number of health care acquired infections related to a specific,

and denominators are device-days collected from all patients, as pooled data; that is, without determining the number of device-days related to a particular patient, and without collecting features or characteristics per specific patient. This aspect differs from the ISOS, because the design of the cohort study through the ISOS also includes the ICPs' collecting of specific data per patient from *all* patients, both those with and those without PVC-BSI, such as invasive devices utilization, age, gender, date of admission, date of discharge, LOS, microorganism profile of HAIs, bacterial resistance, and mortality, among several others.

### Outcome surveillance data collection and validation

This study presents the results of Outcome Surveillance of PVC-BSIs in the ICU through the use of the ISOS, which follows the INICC protocol and allows the classification of prospective, active, cohort data into specific module protocols.

The site-specific criteria include reporting instructions and provide full explanations integral to their adequate application.

All patients with usage of a central line were excluded from this study. Only patients with PVC were included in this study.

ICPs collected daily data on PVC-BSIs, and denominator data, such as specific device-days in the ICUs, patient-days, microorganism profile, and bacterial resistance.

Validation is an essential feature of the ISOS to maximize the sensitivity and accuracy of surveillance data. Each PVC-BSI reported by an ICP is validated (i.e., scrutinized to be certain that all criteria are satisfied to justify its recording as a PVC-BSI). The validation process also includes data reported for putatively uninfected patients to permit detection of unreported but true PVC-BSIs. To do that, the ISOS shows an online message to the ICPs asking them to check the criteria for that putative PVC-BSI [17].

### Training

The INICC team trained and provided ICPs with manuals, training tools and tutorial movies, which described in detail how to perform surveillance and upload surveillance data through the ISOS.

In addition, investigators attended webinars, and had continuous access to a support team at the INICC headquarters in Buenos Aires, Argentina. The INICC support team evaluates on a routine basis that ICPs perform surveillance correctly through the ISOS online platform, and sends emails and shows online messages to ICPs asking them to check and review surveillance data and specific criteria.

### Definitions

#### BSI

We used U.S. CDC/NHSN's definition for BSI: "A Laboratory Confirmed Bloodstream Infection (LCBSI) that is not secondary to an infection at another body site" [19–22].

#### LCBSI

We used U.S. CDC/NHSN's definition for LCBSI: "Patient of any age has a recognized bacterial or fungal pathogen, not included on the NHSN common commensal list: 1. Identified from one or more blood specimens obtained by a culture OR 2. Identified to the genus or species level by non-culture based microbiologic testing (NCT) methods (for example, T2 Magnetic Resonance [T2MR] or Karius Test). [Note: If blood is collected for culture within 2 days before, or 1 day after the NCT, disregard the result of the NCT and use only the result of the CULTURE to make an LCBSI surveillance determination. If no blood is collected for culture within this time period, use the

result of the NCT for LCBI surveillance determination.), AND Organism(s) identified in blood is not related to an infection at another site” [19–22].

#### PVCR-BSI

U.S. CDC/NHSN's definitions do not include the surveillance definition of PVCR-BSI [19–22]. We applied the CDC/NHSN's definition for patients that met all the criteria for BSI, but never used central lines, nor peripherally inserted central catheters, and that only used short term PVCs, before and or after the acquisition of a BSI.

#### Calculation

Data uploaded to ISOS were used to calculate PVCR-BSI rates per 1000 device-days, mortality, and LOS, according to the following formulas: device-days consisted of the total number of PVC-days.

Crude excess mortality of PVCR-BSI equaled crude mortality of ICU patients with PVCR-BSI minus crude mortality of patients without PVCR-BSI.

Crude excess LOS of PVCR-BSI equaled crude LOS of ICU patients with PVCR-BSI minus crude LOS of patients without PVCR-BSI.

Device utilization ratio (DUR) equaled the total number of PVCR-days divided by the total number of bed days.

To calculate extra LOS and extra mortality, all central line-associated BSIs were excluded, and only patients with PVCs, both with or without BSIs, were included.

#### Statistical analysis

ISOS version 2.0 (Buenos Aires, Argentina), was used to calculate PVCR-BSI rates, DURs, LOS and mortality. EpiInfo® version 6.04b (CDC, Atlanta, GA), SPSS 16.0 (SPSS Inc. an IBM company, Chicago, Illinois). 95% confidence intervals (CIs) and P-values were determined for all outcomes.

#### Setting

The study was conducted in 246 ICUs from 83 hospitals in 52 cities of the following 14 countries from the Middle East Middle East: Bahrain, Egypt, Iran, Jordan, Kingdom of Saudi Arabia, Kuwait, Lebanon, Morocco, Pakistan, Palestine, Sudan, Tunisia, Turkey, and United Arab Emirates.

**Table 2**

Pooled means, 95% confidence intervals of the distribution of short-term peripheral venous catheter-related bloodstream infections rates by type of location, in adult and pediatric intensive care units.

Type of ICU	ICU, n	Patients, n	Bed days, n	PVCR-BSIs, n	PVC days, n	Pooled PVCR-BSI rate	Device utilization ratio			
							Mean	95% CI	SD	
Burn	2	3	10	0	15	0.00	1.58	0.29	2.88	0.52
Cardiothoracic	2	66	337	0	334	0.00	1.02	0.96	1.08	0.23
Coronary	14	2116	9280	7	9607	0.73	1.08	1.06	1.10	0.43
Medical	55	2209	16,506	71	18,238	3.89	1.10	1.07	1.12	0.54
Medical/surgical	90	20,182	120,467	247	12,9386	1.91	1.11	1.10	1.12	0.67
Neuro surgical	6	55	937	3	1031	2.91	1.15	0.95	1.36	0.75
Neurologic	4	17	245	2	250	8.00	1.08	0.89	1.28	0.38
Oncology	2	975	3433	77	6784	11.35	1.98	1.96	2.01	0.35
Other	10	19	68	2	73	27.40	1.19	0.79	1.59	0.82
Pediatric	22	3956	28,753	34	26,551	1.28	1.04	1.02	1.05	0.40
Pediatric oncology	3	351	1416	1	1274	0.78	0.92	0.90	0.95	0.23
Respiratory	6	13	89	0	112	0.00	1.09	0.91	1.28	0.31
Surgical	22	1026	7408	23	8034	2.86	1.16	1.12	1.20	0.61
Trauma	8	95	885	3	686	4.37	0.93	0.87	0.98	0.27
Pooled (adult and pediatric ICUs)	246	31,083	189,834	470	202375	2.32	1.123	1.116	1.129	.622

ICU, intensive care unit; PVCR-BSI, short-term peripheral venous catheter-related bloodstream infections; PVC, short-term peripheral venous catheter; DU, device utilization; CI, confidence interval; SD, standard deviation.

**Table 1**  
Type of ICU and hospitals' ownership.

ICUs, type	No. of ICUs	%
Burn	2	<b>0.81</b>
Cardiothoracic	2	<b>0.81</b>
Coronary	14	<b>5.69</b>
Medical	55	<b>22.36</b>
Medical/surgical	90	<b>36.59</b>
Neuro surgical	6	<b>2.44</b>
Neurologic	4	<b>1.63</b>
Oncology	2	<b>0.81</b>
Pediatric	22	<b>8.94</b>
Pediatric oncology	3	<b>1.22</b>
Respiratory	6	<b>2.44</b>
Surgical	22	<b>8.94</b>
Trauma	8	<b>3.25</b>
Other	10	<b>4.07</b>
Total	246	100
Hospitals		
Academic teaching, n, %	11	<b>13.25</b>
Public, n, %	55	<b>66.27</b>
Private community, n, %	17	<b>20.48</b>
Total hospitals, n, %	83	100

ICU, intensive care unit.

All the cohort of patients admitted to the ICUs during the study period was enrolled in the study with hospitals' Research Ethics Committees approval.

In accordance with the INICC's Charter, the identity of all INICC hospitals and cities is kept confidential [17].

#### Results

During the study period of 6 years, from September 1<sup>st</sup>, 2013 to 31<sup>st</sup> May, 2019, the mean length of participation of the ICUs was 22 months (SD: 25.3), range from 2 to 149 months.

Table 1 shows type of ICUs and type of hospitals' ownership.

Table 2 shows PVCR-BSI rates and DURs by type of ICU. Overall PVCR-BSI rate was 2.32 per 1000 PVC days. The PVCR-BSI rate including only Oncology ICUs was 11.35. The PVCR-BSI rate without including Oncology ICUs was 2.01 (393 PVCR-BSIs/195576 PVC days × 1000).

Table 3 provides data on crude ICU mortality and crude LOS in patients with and without PVCR-BSI.



**Table 3**  
Pooled means of the distribution of crude mortality and length of stay of intensive care unit patients with short-term peripheral venous catheter-related bloodstream infections in adult and pediatric intensive care units combined.

	No. of deaths	No. of patients	Pooled crude mortality, % (mean; standard deviation; 95% CI)	LOS, total days	Pooled mean LOS, days, (standard deviation; 95% CI)
Adult and pediatric patients, without PVCr-BSI	3,179	30,613	10.38% (0.1; 0.31; 0.10–0.11)	181,919	5.94 (8.98; 5.90–5.98)
Adult and pediatric patients, with PVCr-BSI	138	470	29.36% (0.29; 0.46; 0.29–0.30)	7,915	16.84 (23.39; 16.73– 16.95)
Total	3,317	31,083	–	189,834	–

PVCr-BSI, short-term peripheral venous catheter-related bloodstream infections; LOS, length of stay; CI, confidence interval.

**Table 4**  
Antimicrobial resistance rates in intensive care units.

	PVCr-BSI	
<i>Pseudomonas aeruginosa</i>		
PIP or TZP		
AMK		
IPM or MEM		
<i>Klebsiella pneumoniae</i>		
CRO or CAZ		
FQs	11	72.73 (8)
<i>Escherichia coli</i>		
<i>Staphylococcus aureus</i>		
OXA	14	50.00 (7)
<i>Enterococcus faecalis</i>		
VAN	2	0.0 (0)

PVC, short-term peripheral venous catheter; PVCr-BSI, PVC-related bloodstream infections; infection; FQs, fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin, or ofloxacin); OXA, oxacillin; PIP, piperacillin; TZP, piperacillin-tazobactam; AMK, amikacin; VAN, vancomycin; IPM, imipenem; MEM, meropenem; CRO, ceftriaxone; CAZ, ceftazidime; ETP, ertapenem.


Table 4 provides data on bacterial resistance of pathogens isolated from patients with PVCr-BSI in adult and pediatric ICUs.

Fig. 1 shows microorganism profile of PVCr-BSIs.

## Discussion

To date, there are not published data available from representative studies analyzing PVCr-BSI rates in countries from the Middle East nor in any of the other five regions of the WHO. Our six-year study, including data of 149,609 patients from 246 ICUs, in 83 hospitals, in 52 cities of 14 countries, is the first comprehensive one to determine PVCr-BSI rates per 1000 device-days in this region [5]. The pooled mean PVCr-BSI rate was 2.32 per 1000 PVC-days; however, there was heterogeneity in PVCr-BSI rates across the different types of ICU, as shown by the 11.35 PVCr-BSI rate including only Oncology ICUs. The PVCr-BSI rate without including Oncology ICUs was 2.01. As far as we are concerned, the incidence of PVCr-BSI has been determined by number of PVC-days in only two studies back in 2006, in a systematic review with data from only three countries (the US, Australia, and Italy), the rate was 0.5 PVCr-BSI per 1000 PVC-days [12]; and in a recent study conducted in pediatric and neonatal ICUs from Australia, the rate was 0.67 PVCr-BSI per 1000 PVC-days [13].

In a systematic review published in 2019 by Alliance for Vascular Access Teaching and Research (AVATAR) group the selected studies did not report PVC-days as denominators of PVCr-BSIs rates, and for that reason such data is not comparable with our present



**Fig. 1.** Microorganism profile of short-term peripheral venous catheter-related bloodstream infections.

\*Other gram negative bacteria: It includes the following microorganisms that individually accounted for <1%: *Aeromonas* sp., *Bacteroides fragilis*, *Burkholderia cepacia*, *Citrobacter freundii*, *Citrobacter* spp., *Escherichia* sp., *Klebsiella* sp., *Kluyvera intermedia*, *Legionella pneumophila*, *Morganella morganii*, *Proteus* spp., *Pseudomonas fluorescens*, *Salmonella* spp., *Serratia marcescens*, *Shigella* sp., *Stenotrophomonas maltophilia*, and *Stenotrophomonas* sp.

\*\*Other gram positive bacteria: It includes the following microorganisms that individually accounted for <1%: *Aerococcus* spp., *Corynebacterium jeikeium*, Methicillin-resistant *Staphylococcus aureus*, *S. epidermidis*, *Streptococcus Beta Hemolytic*, *agalactiae*, *Streptococcus mitis*, *Streptococcus pneumoniae*, *Streptococcus* sp., and *Viridans group Streptococci*.

study [23]. The cited review published by AVATAR included studies whose PVCN-BSI rates were presented as follows [23]: Australia (0.39 PVCN-BSI per 10,000 occupied bed-days) [24]; Germany (3.04 PVCN-BSI per 1000 patient days) [25]; Spain (1.17 PVCN-BSI per 10,000 patient days) [26], and 0.05 PVCN/1000 patient days [27]; and USA (0.0150 PVCN-BSI per 100 patient days) [28], and 0.57 PVCN-BSI per 1000 patient days) [29].

Most studies have reported on the adverse consequences of BSIs in ICUs, and the comparison of infection risk using central lines (CL) versus PVCs, with CLs being much more prone to higher BSIs rates than with PVCs [30–32].

In 2016, INICC published data of central line-associated BSI (CLABSI) in 50 countries, prospectively collected during 6 years, from 2010 to 2015, from 861,284 ICU patients for 3,506,562 bed-days. Pooled rates for adult and pediatric ICUs were 4.1 CLABSIs per 1000 central line-days [6]. The comparison of INICC these previous data published in 2016 of CLABSI with this study's INICC present data on PVCN-BSI shows the pooled rate of CLABSI is 70% higher than the PVCN-BSI rate. However, since around 80%–90% of the vascular catheters used worldwide are PVCs, the raw number of BSIs due to PVC is around six times higher than due to CL [33].

In our ICUs, the pooled mean of the distribution of crude mortality amounted to 29.36% of PVCN-BSIs cases, compared with 10.38% mortality of with PVC patients that were not infected. In recent studies from Spain and Japan, mortality attributable to PVCN-BSI was 13.2% and 12.9%, respectively [26,34]. The excess LOS of patients with PVCN-BSI (16.84) was almost three-fold higher than in patients without PVCN-BSI (5.94); in the previously cited study from Japan, patients who had acquired PVCN-BSI required a longer duration of antibiotic treatment (33.5 vs. 15.8 days;  $p = 0.004$ ) than patients without PVCN-BSI [34].

The microorganism profile showed 55.2% of gram-positive bacteria, with Coagulase-negative *Staphylococci* (31%) and *Staphylococcus aureus* (14%) being the predominant ones. Gram-negative bacteria accounted for 39% of cases, and included: *Escherichia coli* (7%), *Klebsiella pneumoniae* (8%), *Pseudomonas aeruginosa* (5%), *Enterobacter* spp. (3%), and others (29.9%), such as *Serratia marcescens*.

The predominance of gram positive pathogens causing PVCN-BSI has been found in a wide range of studies [35], in which *Staphylococcus aureus* PVCN-BSI has been identified as a serious condition that could influence prognosis [26,34,36].

The most prevalent PVCN-BSI pathogens found presented considerable resistance rates. Resistance of *Pseudomonas aeruginosa* to fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin, or ofloxacin) was 33.33%, to piperacillin, piperacillin-tazobactam, 28.57%, to amikacin, 28.57%, and to imipenem (IPM) or meropenem (MEM), it was 14.28%; of *Acinetobacter baumannii* to IPM or MEM was 58.33% and to fluoroquinolones it was 72.73%; of *Klebsiella pneumoniae* to ceftazidime or ceftazidime was 58.82%, and to IPM or MEM or ertapenem, it was 20.00%; of *Escherichia coli* to ceftazidime or ceftazidime, it was 50.00%, to IPM or MEM or ertapenem, it was 0.00%, and to fluoroquinolones, it was 77.78%.

Regarding gram-positive bacteria, in our study, resistance of *Staphylococcus aureus* to oxacillin in 50.00% of cases which is similar to a 49% resistance reported in a study conducted in India [37]. *Enterococcus faecalis* was 100% sensitive to vancomycin, which is similar to the findings of the mentioned study conducted in India, in which vancomycin was 100% sensitive to PVCN-BSI *Enterococcus* spp [37].

The implementation of PVC insertion and maintenance bundles to decrease PVCN-BSI rates is common worldwide [23,26]. To reduce the hospitalized patients' risk of infection, PVCN-BSI surveillance by number of device-days is essential, because it effectively characterizes the threatening situation created by PVCN-BSIs.

This must be followed by the implementation of multifaceted and surveillance programs aimed at PVCN-BSI prevention and control.

Likewise, it is important to address the burden of antimicrobial resistance and report susceptibility to antimicrobials of PVCN-BSI-associated pathogens, to take effective measures to prevent resistant strains from being transmitted [23,26].

In this particular study, INICC focused just on the ICU setting; that is, healthcare settings with the highest healthcare-acquired rates, in which patients' safety is most seriously threatened, due to their critical condition and exposure to invasive devices [38]. Through the last 17 years, INICC has undertaken a global effort in the six WHO regions: Africa, the Americas, Eastern Mediterranean, Europe, South East Asia, and Western Pacific to respond to the burden of HAIs, and has achieved extremely successful results, by increasing hand hygiene compliance, improving compliance with infection control bundles and interventions as described in several INICC publications [39–45].

The primary application of these data is to serve as a guide for the implementation of prevention strategies and other quality improvement efforts for the reduction of PVCN-BSI rates and their related adverse events to the minimum possible level.

#### Study limitations

The purpose of this study was to obtain updated data on PVCN-BSI, device utilization ratio, bacterial resistance, LOS and mortality of patients with and without PVCN-BSI in adult and pediatric ICUs, but it does not provide insights regarding the impact of INICC interventions, such as the implementation of INICC Multidimensional Approach and ISOS [17,46]. The impact of the adoption of such resources is to be published in prospective, interventional studies at hospitals that have participated in INICC during a considerable amount of years [41,44,45,47–50,52–64]. Second, our study was limited by the fact that benchmarking with CDC-NSHN, or other institutions, was not possible because PVCN-BSI rates are not reported to such institutions, or are not determined by PVC-days [65,66]. Third, probably cultures taken were less than ideal, which likely influenced the rates of PVCN-BSI, and the number of patients to whom blood cultures should have been taken, but were not, is unknown as this data was not registered. In addition, healthcare workers' level of compliance with preventive measures may have changed during the study period, but this was not measured. Fourth, resistance rates cannot be generalized due to the small sample size. Fifth, to define LOS in patients with and without BSI, the time of origin was counted from the first day of admission to the ICU, and it is not possible to know if the longer LOS was the cause or the consequence of BSI. Finally, we do not present data on trends over time for this 6-year study.

#### Conclusions

This study presents the only available comprehensive data from Middle East showing PVCN-BSIs per 1000 PVC-days, and benchmarking of our findings was limited to the results of two studies the US, Australia, and Italy published in 2006 [12], and a prospective study from Australia [13]. Our PVCN-BSI rates were far much higher than the data available from USA, Australia and Italy, thereby it is evident that PVCN-BSIs in ICUs worldwide are a challenge for patient safety. PVCN-BSI systematic surveillance and prevention programs, including antibiotic resistance reports, should be widely implemented to allow a reduction in the incidence of PVCN-BSI and its adverse-related events worldwide.

## Author contributions

All authors were involved in drafting of the manuscript, provision of study patients, collection of data, critical revision of the manuscript for important intellectual content, and final approval of the manuscript. V.D.R. was responsible for study conception and design; software development; data assembly, analysis, and interpretation; epidemiologic analysis; statistical analysis; administrative, technical, and logistical support.

## Funding

The funding for the activities carried out at INICC head quarters were provided by the corresponding author, Victor D. Rosenthal, and the Foundation to Fight against Nosocomial Infections.

## Competing interests

All authors report no conflicts of interest related to this article. Institutional Review Boards agreed to the study protocol, and patient confidentiality was protected by codifying the recorded information, making it only identifiable to the infection control team.

## Ethical approval

Not required.

## Acknowledgments

The authors thank the many healthcare professionals at each member hospital who assisted with the conduct of surveillance in their hospital; Débora López Burgardt, who work at INICC headquarters in Buenos Aires; the INICC Country Directors and Secretaries (Haifaa Hassan Al-Mousa, Hail Alabdaley, Altaf Ahmed, Anucha Apisarnthanarak, Bijie Hu, Hakan Leblebicioglu, Yatin Mehta, Toshihiro Mitsuda, and Lul Raka.); and the INICC Advisory Board (Carla J. Alvarado, Nicholas Graves, William R. Jarvis, Patricia Lynch, Dennis Maki, Toshihiro Mitsuda, Russell N. Olmsted, William Rutala, Syed Sattar, and Wing Hong Seto), who have so generously supported this unique international infection control network.

## Appendix A

Appendix with remaining co-authors

## References

- [1] Helm RE, Klausner JD, Klemperer JD, Flint LM, Huang E. Accepted but unacceptable: peripheral IV catheter failure. *J Infus Nurs* 2019;42(May/June (3)):151–64.
- [2] Sabri A, Szalas J, Holmes KS, Labib L, Mussivand T. Failed attempts and improvement strategies in peripheral intravenous catheterization. *Biomed Mater Eng* 2013;23(1–2):93–108.
- [3] Mermel LA. Short-term peripheral venous catheter–related bloodstream infections: a systematic review. *Clin Infect Dis* 2017;65(10):1757–62.
- [4] Wallis MC, McGrail M, Webster J, Marsh N, Gowardman J, Playford EG, et al. Risk factors for peripheral intravenous catheter failure: a multivariate analysis of data from a randomized controlled trial. *Infect Control Hosp Epidemiol* 2014;35(January (1)):63–8.
- [5] Alexandrou E, Ray-Barruel G, Carr PJ, Frost SA, Inwood S, Higgins N, et al. Use of short peripheral intravenous catheters: characteristics, management, and outcomes worldwide. *J Hosp Med* 2018;13(May (5)).
- [6] Rosenthal VD, Al-Abdely HM, El-Kholy AA, AlKhawaja SAA, Leblebicioglu H, Mehta Y, et al. International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010–2015: device-associated module. *Am J Infect Control* 2016;44(December (12)):1495–504.
- [7] Rosenthal VD, Lynch P, Jarvis WR, Khader IA, Richtmann R, Jaballah NB, et al. Socioeconomic impact on device-associated infections in limited-resource neonatal intensive care units: findings of the INICC. *Infection* 2011;39(October (5)):439–50.
- [8] Rosenthal VD, Jarvis WR, Jamulitrat S, Silva CP, Ramachandran B, Duenas L, et al. Socioeconomic impact on device-associated infections in pediatric intensive care units of 16 limited-resource countries: International Nosocomial Infection Control Consortium findings. *Pediatr Crit Care Med* 2012;13(July (4)):399–406.
- [9] Abolfotouh MA, SalaCm M, Bani-Mustafa Aa, White D, Balkhy HH. Prospective study of incidence and predictors of peripheral intravenous catheter-induced complications. *Ther Clin Risk Manag* 2014;10:993–1001.
- [10] Zhang L, Cao S, Marsh N, Ray-Barruel G, Flynn J, Larsen E, et al. Infection risks associated with peripheral vascular catheters. *J Infect Prev* 2016;17(5):207–13.
- [11] O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections. *Clin Infect Dis* 2011;52(9):e162–93.
- [12] Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. *Mayo Clin Proc* 2006;81(September (9)):1159–71.
- [13] Worth LJ, Daley AJ, Spelman T, Bull AL, Brett JA, Richards MJ. Central and peripheral line-associated bloodstream infections in Australian neonatal and paediatric intensive care units: findings from a comprehensive Victorian surveillance network, 2008–2016. *J Hosp Infect* 2018;99(May (1)):55–61.
- [14] Infusion Nurses Society. Infusion therapy standards of practice. In: *Nursing INSoP*, editor. Infusion nursing standards of practice: journal of infusion nursing, 5th edition ed. Infusion Nurses Society; 2016.
- [15] Rosenthal VD, Kanj SS, Desse J, AlKhawaja S, Cimerman S, Rodriguez Morales AJ, et al. Bundle of the International Nosocomial Infection Control Consortium (INICC) to Prevent Central and Peripheral Line-Related Bloodstream Infections 2019.
- [16] Rosenthal VD, Maki DG, Mehta Y, Leblebicioglu H, Memish ZA, Al-Mousa HH, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 43 countries for 2007–2012. Device-associated module. *Am J Infect Control* 2014;42(May (9)):942–56.
- [17] Rosenthal VD. International Nosocomial Infection Control Consortium (INICC) resources: INICC multidimensional approach and INICC surveillance online system. *Am J Infect Control* 2016;44(June (6)):e81–90.
- [18] National Healthcare Safety Network (NHSN), Available from: Patient safety component manual: Centers for Disease Control and Prevention; 2019 <https://www.cdc.gov/nhsn/pdfs/pdscmanual/pdscmanual.current.pdf>.
- [19] CDC/NHSN. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. 2019. Available from: <http://www.cdc.gov/nhsn/>. [cited 6 July 2019].
- [20] CDC/NHSN. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. 2017. Available from: <http://www.cdc.gov/nhsn/>. [updated Jan 2017; cited 6 March 2017].
- [21] CDC/NHSN. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. 2016. Available from: <http://www.cdc.gov/nhsn/>. [updated Jan 2016; cited 3 March 2016].
- [22] CDC/NHSN. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. 2013. Available from: <http://www.cdc.gov/nhsn/>. [updated January 2013 August 2015].
- [23] Ray-Barruel G, Xu H, Marsh N, Cooke M, Rickard CM. Effectiveness of insertion and maintenance bundles in preventing peripheral intravenous catheter-related complications and bloodstream infection in hospital patients: a systematic review. *Infect Dis Health* 2019;24(3):152–68. <http://dx.doi.org/10.1016/j.idh.2019.03.001>, 2019/04/24.
- [24] Rhodes D, Cheng AC, McLellan S, Guerra P, Karanfilovska D, Aitchison S, et al. Reducing *Staphylococcus aureus* bloodstream infections associated with peripheral intravenous cannulae: successful implementation of a care bundle at a large Australian health service. *J Hosp Infect* 2016;94(1):86–91.
- [25] Salm F, Schwab F, Geffers C, Gastmeier P, Piening B. The implementation of an evidence-based bundle for bloodstream infections in neonatal intensive care units in Germany: a controlled intervention study to improve patient safety. *Infect Control Hosp Epidemiol* 2016;37(7):798–804.
- [26] Saliba P, Hornero A, Cuervo G, Grau I, Jimenez E, Berbel D, et al. Interventions to decrease short-term peripheral venous catheter-related bloodstream infections: impact on incidence and mortality. *J Hosp Infect* 2018;100(Nov (3)):e178–86.
- [27] Freixas N, Bella F, LimÃ3n E, Pujol M, Almirante B, Gudiol F. Impact of a multimodal intervention to reduce bloodstream infections related to vascular catheters in non-ICU wards: a multicentre study. *Clin Microbiol Infect* 2013;19(9):838–44, 2019/07/12.
- [28] DeVries M, Valentine M, Mancos P. Protected clinical indication of peripheral intravenous lines: successful implementation. *J Assoc Vasc Access* 2016;21(2):89–92.
- [29] Duncan M, Warden P, Bernatchez Sp F, Morse D. A bundled approach to decrease the rate of primary bloodstream infections related to peripheral intravenous catheters. *J Assoc Vasc Access* 2018;23(1):15–22.
- [30] Miliari K, Taravella R, Thillard D, Chauvin V, Martin E, Edouard S, et al. Peripheral venous catheter-related adverse events: evaluation from a multicentre epidemiological study in France (the CATHEVAL project). *PLoS One* 2017;12(1):e0168637.
- [31] Collignon PJ, Kimber FJ, Beckingham WD, Roberts JL. Prevention of peripheral intravenous catheter-related bloodstream infections: the need for routine replacement. *Med J Aust* 2013;199(December (11)):750–1.



- [32] McKinley L, Davidson B, Broome C, Schenk J, Safdar N. 72–96 hours peripheral venous catheter replacement recommendation: is a single reference enough? *Am J Infect Control* 2007;35(5):E58, 2019/07/03.
- [33] Mehta Y, Jaggi N, Rosenthal VD, Kavathekar M, Sakle A, Munshi N, et al. Device-associated infection rates in 20 cities of India, data summary for 2004–2013: findings of the international nosocomial infection control consortium. *Infect Control Hosp Epidemiol* 2016;37(February (2)):172–81.
- [34] Sato A, Nakamura I, Fujita H, Tsukimori A, Kobayashi T, Fukushima S, et al. Peripheral venous catheter-related bloodstream infection is associated with severe complications and potential death: a retrospective observational study. *BMC Infect Dis* 2017;17(1):434.
- [35] Elsayed S, Laupland KB. Emerging gram-positive bacterial infections. *Clin Lab Med* 2004;24(September (3)):587–603.
- [36] Austin ED, Sullivan SB, Whittier S, Lowy FD, Uhlemann AC. Peripheral intravenous catheter placement is an underrecognized source of *Staphylococcus aureus* bloodstream infection. *Open Forum Infect Dis* 2016;3(March (2)):ofw072.
- [37] Dalai SK, Padhi S, Padhi A, Parida B. Peripheral venous catheter related blood stream infection in intensive care unit. *Int J Ad Med* 2018;5(May–June (3)):668–73.
- [38] Rosenthal VD, Maki DG, Salomao R, Moreno CA, Mehta Y, Higuera F, et al. Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. *Ann Intern Med* 2006;145(October (8)):582–91.
- [39] Rosenthal VD, Alvarez-Moreno C, Villamil-Gomez W, Singh S, Ramachandran B, Navoa-Ng JA, et al. Effectiveness of a multidimensional approach to reduce ventilator-associated pneumonia in pediatric intensive care units of 5 developing countries: international Nosocomial Infection Control Consortium findings. *Am J Infect Control* 2012;40(August (6)):497–501.
- [40] Rosenthal VD, Rodrigues C, Alvarez-Moreno C, Madani N, Mitrev Z, Ye G, et al. Effectiveness of a multidimensional approach for prevention of ventilator-associated pneumonia in adult intensive care units from 14 developing countries of four continents: findings of the International Nosocomial Infection Control Consortium. *Crit Care Med* 2012;40(December (12)):3121–8.
- [41] Rosenthal VD, Ramachandran B, Villamil-Gomez W, Armas-Ruiz A, Navoa-Ng JA, Matta-Cortes L, et al. Impact of a multidimensional infection control strategy on central line-associated bloodstream infection rates in pediatric intensive care units of five developing countries: findings of the International Nosocomial Infection Control Consortium (INICC). *Infection* 2012;40(August (4)):415–23.
- [42] Rosenthal VD, Bijie H, Maki DG, Mehta Y, Apisarnthanarak A, Medeiros EA, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004–2009. *Am J Infect Control* 2012;40(June (5)):396–407.
- [43] Rosenthal VD, Maki DG, Rodrigues C, Alvarez-Moreno C, Leblebicioglu H, Sobreyra-Oropeza M, et al. Impact of International Nosocomial Infection Control Consortium (INICC) strategy on central line-associated bloodstream infection rates in the intensive care units of 15 developing countries. *Infect Control Hosp Epidemiol* 2010;31(December (12)):1264–72.
- [44] Rosenthal VD, Rodriguez-Calderon ME, Rodriguez-Ferrer M, Singhal T, Pawar M, Sobreyra-Oropeza M, et al. Findings of the International Nosocomial Infection Control Consortium (INICC), part II: impact of a multidimensional strategy to reduce ventilator-associated pneumonia in neonatal intensive care units in 10 developing countries. *Infect Control Hosp Epidemiol* 2012;33(Jul (7)):704–10.
- [45] Rosenthal VD, Duenas L, Sobreyra-Oropeza M, Ammar K, Navoa-Ng JA, de Casares AC, et al. Findings of the International Nosocomial Infection Control Consortium (INICC), part III: effectiveness of a multidimensional infection control approach to reduce central line-associated bloodstream infections in the neonatal intensive care units of 4 developing countries. *Infect Control Hosp Epidemiol* 2013;34(March (3)):229–37.
- [46] Rosenthal VD, Maki DG, Graves N. The International Nosocomial Infection Control Consortium (INICC): goals and objectives, description of surveillance methods, and operational activities. *Am J Infect Control* 2008;36(November (9)):e1–12.
- [47] Rosenthal VD, Desse J, Maurizi DM, Chaparro GJ, Orellano PW, Chediack V, et al. Impact of the International Nosocomial Infection Control Consortium's multidimensional approach on rates of ventilator-associated pneumonia in 14 intensive care units in 11 hospitals of 5 cities within Argentina. *Am J Infect Control* 2018;6553(17):31290–7.
- [48] Rosenthal VD, Desse J, Maurizi DM, Chaparro GJ, Orellano PW, Chediack V, et al. Impact of the International Nosocomial Infection Control Consortium (INICC)'s multidimensional approach on rates of central line-associated bloodstream infection in 14 intensive care units in 11 hospitals of 5 cities in Argentina. *Infect Control Hosp Epidemiol* 2018;12:1–7.
- [49] Al-Mousa HH, Omar AA, Rosenthal VD, Salama MF, Aly NY, El-Dossoky Noweir M, et al. Impact of the International Nosocomial Infection Control Consortium (INICC) multidimensional approach on rates of ventilator-associated pneumonia in intensive care units of two hospitals in Kuwait. *J Infect Prev* 2018;19(July (4)):168–76.
- [50] Al-Abdely HM, Alshehri AD, Rosenthal VD, Mohammed YK, Banjar W, Orellano PW, et al. Impact of the international nosocomial infection control consortium (INICC)'s multidimensional approach on rates of ventilator-associated pneumonia in intensive care units in 22 hospitals of 14 cities of the Kingdom of Saudi Arabia. *J Infect Public Health* 2018;11(5):677–84, <http://dx.doi.org/10.1016/j.jiph.2018.06.002>.
- [52] Gan CS, Rai V, Rosenthal VD, Lucy Chai See Lum LCS, Orellano PW, Chuah SL, et al. Multicenter study in Malaysia: impact of a multidimensional International Nosocomial Infection Control Consortium (INICC) approach on ventilator-associated pneumonia rates and mortality in intensive care units. *Can J Infect Control* 2016;31(4):230–6.
- [53] Alvarez-Moreno CA, Valderrama-Beltran SL, Rosenthal VD, Mojica-Carreno BE, Valderrama-Marquez IA, Matta-Cortes L, et al. Multicenter study in Colombia: impact of a multidimensional International Nosocomial Infection Control Consortium (INICC) approach on central line-associated bloodstream infection rates. *Am J Infect Control* 2016;44(November (11)):e235–41.
- [54] Al-Abdely HM, Alshehri AD, Rosenthal VD, Mohammed YK, Banjar W, Orellano PW. Multicenter study in intensive care units in 5 cities from Kingdom of Saudi Arabia: impact of the International Nosocomial Infection Control Consortium (INICC) multidimensional approach on rates of central line associated infection. *J Infect Prev* 2016;18(1):25–34, <http://dx.doi.org/10.1177/1757177416669424>.
- [55] Mehta Y, Jaggi N, Rosenthal VD, Rodrigues C, Todi SK, Saini N, et al. Effectiveness of a multidimensional approach for prevention of ventilator-associated pneumonia in 21 adult intensive-care units from 10 cities in India: findings of the International Nosocomial Infection Control Consortium (INICC). *Epidemiol Infect* 2013;12(March):1–9.
- [56] Leblebicioglu H, Yalcin AN, Rosenthal VD, Koksali S, Sirmatel F, Unal S, et al. Effectiveness of a multidimensional approach for prevention of ventilator-associated pneumonia in 11 adult intensive care units from 10 cities of Turkey: findings of the International Nosocomial Infection Control Consortium (INICC). *Infection* 2013;41(April (2)):447–56.
- [57] Leblebicioglu H, Ozturk R, Rosenthal VD, Akan OA, Sirmatel F, Ozdemir D, et al. Impact of a multidimensional infection control approach on central line-associated bloodstream infections rates in adult intensive care units of 8 cities of Turkey: findings of the International Nosocomial Infection Control Consortium (INICC). *Ann Clin Microbiol Antimicrob* 2013;12:10.
- [58] Leblebicioglu H, Ersoz G, Rosenthal VD, Yalcin AN, Akan OA, Sirmatel F, et al. Impact of a multidimensional infection control approach on catheter-associated urinary tract infection rates in adult intensive care units in 10 cities of Turkey: International Nosocomial Infection Control Consortium findings (INICC). *Am J Infect Control* 2013;41(10):885–91.
- [59] Jaggi N, Rodrigues C, Rosenthal VD, Todi SK, Shah S, Saini N, et al. Impact of an international nosocomial infection control consortium multidimensional approach on central line-associated bloodstream infection rates in adult intensive care units in eight cities in India. *Int J Infect Dis* 2013;17(December (12)):e1218–24.
- [60] Tao L, Hu B, Rosenthal VD, Zhang Y, Gao X, He L. Impact of a multidimensional approach on ventilator-associated pneumonia rates in a hospital of Shanghai: findings of the International Nosocomial Infection Control Consortium. *J Crit Care* 2012;27(October (5)):440–6.
- [61] Rosenthal VD, Todi SK, Alvarez-Moreno C, Pawar M, Karlekar A, Zeggwagh AA, et al. Impact of a multidimensional infection control strategy on catheter-associated urinary tract infection rates in the adult intensive care units of 15 developing countries: findings of the International Nosocomial Infection Control Consortium (INICC). *Infection* 2012;40(October (5)):517–26.
- [62] Rosenthal VD, Rodrigues C, Alvarez-Moreno C, Madani N, Mitrev Z, Ye G, et al. Effectiveness of a multidimensional approach for prevention of ventilator-associated pneumonia in adult intensive care units from 14 developing countries of four continents: findings of the International Nosocomial Infection Control Consortium. *Crit Care Med* 2012;40(December (12)):3121–8.
- [63] Rosenthal VD, Ramachandran B, Duenas L, Alvarez-Moreno C, Navoa-Ng JA, Armas-Ruiz A, et al. Findings of the International Nosocomial Infection Control Consortium (INICC), part I: effectiveness of a multidimensional infection control approach on catheter-associated urinary tract infection rates in pediatric intensive care units of 6 developing countries. *Infect Control Hosp Epidemiol* 2012;33(July (7)):696–703.
- [64] Rosenthal VD, Maki DG, Rodrigues C, Alvarez-Moreno C, Leblebicioglu H, Sobreyra-Oropeza M, et al. Impact of International Nosocomial Infection Control Consortium (INICC) strategy on central line-associated bloodstream infection rates in the intensive care units of 15 developing countries. *Infect Control Hosp Epidemiol* 2010;31(December (12)):1264–72.
- [65] Centers for Disease Control and Prevention. The NHSN Standardized Utilization Ratio (SUR): a guide to the SUR. 2019. Available at <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/nhsn-sur-guide-508.pdf>. [Accessed 25 January 2019].
- [66] Centers for Disease Control and Prevention. The NHSN Standardized Infection Ratio (SIR): a guide to the SIR. 2019. Available at <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/nhsn-sir-guide.pdf>. [Accessed 27 May 2019].